Search

Displaying results 2861 - 2870 of 5900 in total
  1. Drug

    ISS-1018

    go.drugbank.com/drugs/DB05463
    Investigational

    ISS 1018 CpG ODN promotes antigen presentation and co-stimulatory molecule expression. … ISS 1018 is currently being investigated in combination with HBsAg vaccine as a prophylactic treatment for to prevent Hepatitis B in adults.

  2. Drug

    Indinavir

    go.drugbank.com/drugs/DB00224
    ApprovedInvestigational

    A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem]

  3. Drug

    Saxagliptin

    go.drugbank.com/drugs/DB06335
    ApprovedInvestigational

    Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.

  4. Drug

    Paricalcitol

    go.drugbank.com/drugs/DB00910
    ApprovedInvestigational

    Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.

  5. Drug

    Treosulfan

    go.drugbank.com/drugs/DB11678
    ApprovedInvestigational

    Treosulfan is a prodrug alternative to [busulfan] for myeloablative conditioning prior to hematopoietic stem cell transplantation.

  6. Drug

    Pipamperone

    go.drugbank.com/drugs/DB09286
    Investigational

    Synthesized in the year 1984, risperidone’s pharmacological properties were similar to pipamperone’s in that both block more serotonin more potently than dopamine [L1518]. … In an effort to improve [haloperidol]'s pharmacological effects, Janssen discovered that pipamperone, an agent whose pharmacological profile was distinct from haloperidol and all other known antipsychotic

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  7. Drug

    Clorgiline

    go.drugbank.com/drugs/DB04017
    Experimental

    An antidepressive agent and monoamine oxidase inhibitor related to PARGYLINE.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  8. Drug

    Cosibelimab

    go.drugbank.com/drugs/DB15770
    ApprovedInvestigational

    Cosibelimab is a human IgG1 lambda monoclonal antibody directed against programmed death ligand-1 (PD-L1). On December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous c...

  9. Drug

    Pegmusirudin

    go.drugbank.com/drugs/DB19220
    Investigational

    Pegmusirudin is under investigation in clinical trial NCT00074620 (A Clinical Study to Assess the Safety of Peg-hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis).

  10. Drug

    Hydroxycitronellal

    go.drugbank.com/drugs/DB14187
    Approved

    Sensitivity to hydroxycitronellal may be identified with a clinical patch test. … Hydroxycitronellal has also been shown to be a dermatologic irritant and allergen, and as a result commercially available products are restricted by the International Fragrance Association (IFRA) to contain